GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmala Biotech Holdings Inc (XCNQ:MDMA) » Definitions » ROA %

Pharmala Biotech Holdings (XCNQ:MDMA) ROA % : -36.65% (As of Feb. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Pharmala Biotech Holdings ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Pharmala Biotech Holdings's annualized Net Income for the quarter that ended in Feb. 2024 was C$-0.89 Mil. Pharmala Biotech Holdings's average Total Assets over the quarter that ended in Feb. 2024 was C$2.43 Mil. Therefore, Pharmala Biotech Holdings's annualized ROA % for the quarter that ended in Feb. 2024 was -36.65%.

The historical rank and industry rank for Pharmala Biotech Holdings's ROA % or its related term are showing as below:

XCNQ:MDMA' s ROA % Range Over the Past 10 Years
Min: -89.8   Med: -38.49   Max: -25.36
Current: -25.36

During the past 3 years, Pharmala Biotech Holdings's highest ROA % was -25.36%. The lowest was -89.80%. And the median was -38.49%.

XCNQ:MDMA's ROA % is ranked better than
59.15% of 1503 companies
in the Biotechnology industry
Industry Median: -35.81 vs XCNQ:MDMA: -25.36

Pharmala Biotech Holdings ROA % Historical Data

The historical data trend for Pharmala Biotech Holdings's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmala Biotech Holdings ROA % Chart

Pharmala Biotech Holdings Annual Data
Trend Aug21 Aug22 Aug23
ROA %
-89.80 -38.49 -32.89

Pharmala Biotech Holdings Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -12.13 -58.10 -13.66 6.00 -36.65

Competitive Comparison of Pharmala Biotech Holdings's ROA %

For the Biotechnology subindustry, Pharmala Biotech Holdings's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharmala Biotech Holdings's ROA % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharmala Biotech Holdings's ROA % distribution charts can be found below:

* The bar in red indicates where Pharmala Biotech Holdings's ROA % falls into.



Pharmala Biotech Holdings ROA % Calculation

Pharmala Biotech Holdings's annualized ROA % for the fiscal year that ended in Aug. 2023 is calculated as:

ROA %=Net Income (A: Aug. 2023 )/( (Total Assets (A: Aug. 2022 )+Total Assets (A: Aug. 2023 ))/ count )
=-0.78/( (2.33+2.413)/ 2 )
=-0.78/2.3715
=-32.89 %

Pharmala Biotech Holdings's annualized ROA % for the quarter that ended in Feb. 2024 is calculated as:

ROA %=Net Income (Q: Feb. 2024 )/( (Total Assets (Q: Nov. 2023 )+Total Assets (Q: Feb. 2024 ))/ count )
=-0.892/( (2.387+2.481)/ 2 )
=-0.892/2.434
=-36.65 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Feb. 2024) net income data. ROA % is displayed in the 30-year financial page.


Pharmala Biotech Holdings  (XCNQ:MDMA) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Feb. 2024 )
=Net Income/Total Assets
=-0.892/2.434
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-0.892 / 0.36)*(0.36 / 2.434)
=Net Margin %*Asset Turnover
=-247.78 %*0.1479
=-36.65 %

Note: The Net Income data used here is four times the quarterly (Feb. 2024) net income data. The Revenue data used here is four times the quarterly (Feb. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Pharmala Biotech Holdings ROA % Related Terms

Thank you for viewing the detailed overview of Pharmala Biotech Holdings's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharmala Biotech Holdings Business Description

Traded in Other Exchanges
Address
82 Richmond Street East, Toranto, ON, CAN, M5C 1P1
Pharmala Biotech Holdings Inc is focused on manufacturing and sales of MDMA and MDXX Active Pharmaceutical Ingredients (API) for use in clinical research. PharmAla's drug API is manufactured and encapsulated under GMP conditions. The Company generates revenue from the sale of tablets and raw MDMA and MDXX compounds/formulations.
Executives
Perry Tsergas Director
Shane H.d. Morris Director, Senior Officer
Nicholas Kadysh Director, Senior Officer
Fraser Macdonald Director

Pharmala Biotech Holdings Headlines

No Headlines